Login
$DSGN
$9.92 -$0.55 (5.25%) Live

$DSGN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
12 Nov 2026 EFFECT
04 Nov 2026 S-3
04 Nov 2026 424B5
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
03 Aug 2026 10-Q
03 Aug 2026 8-K: Results of Operations and Financial Condition

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027

11 Jun 2026 Form 4: George Simeon, Director

Granted 30,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Schmid John P., Director

Granted 30,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Lappe Rodney W, Director

Granted 30,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Gover Justin D., Director

Granted 30,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Shapiro David, Director

Granted 30,000 Stock Option (right to buy)

11 Jun 2026 Form 4: Berger Heather A., Director

Granted 30,000 Stock Option (right to buy)

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2026, Design Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2026, the record date for the Annual Meeting, 62,441,429 shares of common stock were outstand...

09 Jun 2026 SCHEDULE 13G
18 May 2026 8-K: Other Events

On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”).

15 May 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support